AVITA Medical, Inc.
RCELNasdaq
$5.10
↑ +2.4%Jul 17 close · end-of-day
Price
1Y↓ -4.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$155.8M
Enterprise Value
$187.6M
P/E
—
P/S
2.2
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
-20.4%
Dividend Yield
—
Revenue (TTM)
$72.3M
Net Income (TTM)
-$45.3M
Free Cash Flow (TTM)
-$31.8M
Gross Margin
81.4%
Operating Margin
-54.6%
Net Margin
-62.7%
ROE
195.7%
ROIC
-358.3%
Debt / Equity
-2.0
Net Cash
-$31.9M
Return 1Y
-6.1%
Company profile
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company was incorporated in 2000 and is based in Valencia, California.
- CEO
- James M. Corbett
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 130
- Headquarters
- California
- Website
- avitamedical.com
Management & directors
- O'Toole David DCFO
- Vance Cary GuyPresident and CEO
- Kelsey NicoleChief Legal Officer
Roles derived from SEC Form 4 filings.
Earnings
RCEL Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$19.3M↑ +4.0%
Diluted EPS-$0.35↓ -34.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $29.2M | $34.4M | $50.1M | $64.3M | $71.6M |
| Gross profit | $23.3M | $28.4M | $42.4M | $55.2M | $58.8M |
| Operating income | -$26.5M | -$27.5M | -$42.7M | -$56.6M | -$42.5M |
| Net income | -$26.6M | -$26.7M | -$35.4M | -$61.8M | -$48.6M |
| Diluted EPS | $1.17 | $1.07 | -$1.40 | -$2.39 | -$1.74 |
| Operating cash flow | -$25.9M | -$19.1M | -$38.0M | -$48.9M | -$31.2M |
| Free cash flow | -$26.8M | -$19.5M | -$39.4M | -$58.1M | -$32.2M |
| Gross margin | 79.6% | 82.4% | 84.5% | 85.8% | 82.1% |
| Operating margin | -90.8% | -79.9% | -85.1% | -88.1% | -59.4% |
| Net margin | -90.9% | -77.5% | -70.6% | -96.3% | -67.8% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $15.2M | $19.5M | $18.4M | $18.5M | $18.4M | $17.1M | $17.6M | $19.3M |
| Gross profit | $13.1M | $16.4M | $16.1M | $15.7M | $14.9M | $13.9M | $14.3M | $15.7M |
| Operating income | -$15.6M | -$13.8M | -$10.0M | -$11.8M | -$11.1M | -$9.2M | -$10.4M | -$8.8M |
| Net income | -$15.4M | -$16.2M | -$11.6M | -$13.9M | -$9.9M | -$13.2M | -$11.6M | -$10.6M |
| Diluted EPS | -$0.60 | -$0.62 | -$0.44 | -$0.53 | -$0.38 | -$0.46 | -$0.37 | -$0.35 |
| Operating cash flow | -$12.8M | -$7.2M | -$8.1M | -$10.3M | -$10.2M | -$5.2M | -$5.4M | -$10.1M |
| Free cash flow | -$15.4M | -$11.0M | -$9.7M | -$10.5M | -$10.8M | -$6.2M | -$6.1M | -$10.1M |
| Gross margin | 86.1% | 83.7% | 87.6% | 84.7% | 81.2% | 81.3% | 81.2% | 81.7% |
| Operating margin | -102.8% | -70.6% | -54.1% | -63.9% | -60.5% | -53.6% | -59.1% | -45.7% |
| Net margin | -101.3% | -82.9% | -63.0% | -74.9% | -53.9% | -77.3% | -66.0% | -55.1% |
Company news
Jul 14, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-12 | O'Toole David D· CFO | Award | 2,000 | $3.97 | $7,940.00 | filing |
| 2026-06-09 | Woody Joseph Fralin | Buy | 5,000 | $4.20 | $21,000.00 | filing |
| 2026-06-09 | Woody Joseph Fralin | Buy | 5,000 | $4.18 | $20,900.00 | filing |
| 2026-06-09 | Woody Joseph Fralin | Buy | 5,200 | $4.00 | $20,800.00 | filing |
| 2026-06-03 | Woody Joseph Fralin | Buy | 5,000 | $4.10 | $20,499.50 | filing |
| 2026-06-03 | Woody Joseph Fralin | Buy | 5,000 | $4.09 | $20,449.50 | filing |
| 2026-06-02 | Woody Joseph Fralin | Buy | 5,000 | $4.21 | $21,035.50 | filing |
| 2026-06-02 | Woody Joseph Fralin | Buy | 5,000 | $4.18 | $20,901.00 | filing |
| 2026-06-01 | Woody Joseph Fralin | Buy | 5,000 | $4.34 | $21,700.00 | filing |
| 2026-06-01 | Woody Joseph Fralin | Buy | 5,000 | $4.26 | $21,300.00 | filing |
| 2026-05-29 | O'Toole David D· CFO | Award | 5,000 | $3.05 | $15,257.50 | filing |
| 2026-05-29 | Vance Cary Guy· President and CEO | Award | 5,000 | $3.05 | $15,257.50 | filing |
| 2026-05-20 | O'Toole David D· CFO | Buy | 2,000 | $4.26 | $8,520.00 | filing |
| 2026-05-19 | O'Toole David D· CFO | Buy | 2,000 | $4.24 | $8,480.00 | filing |
| 2026-03-11 | O'Toole David D· CFO | Buy | 1,800 | $4.78 | $8,604.00 | filing |
| 2026-02-19 | O'Toole David D· CFO | Buy | 3,000 | $4.15 | $12,450.00 | filing |
| 2026-02-18 | O'Toole David D· CFO | Award | 105,470 | — | — | filing |
| 2026-02-18 | KELSEY NICOLE· Chief Legal Officer | Award | 98,390 | — | — | filing |
| 2026-01-20 | McNamara Robert | Award | 22,214 | — | — | filing |
| 2026-01-20 | Woody Joseph Fralin | Award | 22,214 | — | — | filing |
| 2026-01-20 | Tarnoff Michael E | Award | 22,214 | — | — | filing |
| 2026-01-20 | COOK JEREMY CURNOCK | Award | 22,214 | — | — | filing |
| 2026-01-20 | Crowe Suzanne | Award | 22,214 | — | — | filing |
| 2026-01-20 | REED JAN STERN | Award | 22,214 | — | — | filing |
| 2026-01-05 | Woody Joseph Fralin | Award | 40,547 | — | — | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.